The distinction of drugs vs cosmetics from a regulatory perspective episode artwork

EPISODE · Jul 27, 2021 · 21 MIN

The distinction of drugs vs cosmetics from a regulatory perspective

from CPHI Podcast Series

As more and more companies operating in the pharmaceutical space are moving into cosmetics, the temptation is to think that life will be much easier from a regulatory and compliance perspective.However, while it is true that pharmaceuticals are more heavily regulated, this does not mean that cosmetics developers can rest on their laurels.The subtle lines between making marketing claims about cosmetics that are deemed allowable and those crossing the line into drug products can often be blurred. The wrong claims can cause a cosmetic product to be misbranded attracting unwanted attention from the US Food and Drug Administration.In this podcast with John Bailey and Catherine Bailey from EAS Consulting, we take a look at the various common compliance issues that can arise when jumping the boundary from drugs to cosmetics.

Episode metadata supplied by the publisher feed · Published Jul 27, 2021

Embed this episode

NOW PLAYING

The distinction of drugs vs cosmetics from a regulatory perspective

0:00 21:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CPHI Podcast Series?

This episode is 21 minutes long.

When was this CPHI Podcast Series episode published?

This episode was published on July 27, 2021.

Can I download this CPHI Podcast Series episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!